Stealth Biotherapeutics Is A Clinical Stage Biotechnology Company Based In Grand Caymancayman Islandsthe Company Is Dedicated To Developing Therapies That Target Mitochondrial Dysfunctionwhich Is Associated With Both Rare Genetic Disorders And Common Age Related Diseaseswith A Team Of Approximately 38 Employeesstealth Biotherapeutics Focuses On Advancing Mitochondrial Medicine To Meet Significant Clinical Needs The Company Is Actively Involved In Clinical Research And Therapeutic Commercializationit Emphasizes Patient Centric Development By Collaborating With Advocacy Groups To Better Understand Patient Experiences And Raise Awareness About Mitochondrial Disordersstealth Biotherapeutics Also Supports Healthcare Education Through Grants And Sponsorshipsproviding Valuable Resources To Clinicians And Patient Communities Stealth Biotherapeutics Is Developing Several Investigational Productsincluding Elamipretidea Peptide In Clinical Trials For Rare Mitochondrial Disorders And Age Related Macular Degenerationother Candidates Include Sbt 272 For Neurodegenerative Diseases And The Sbt 550 Series For Rare Neurological Conditionsthe Company Aims To Address Various Symptoms Associated With Mitochondrial Dysfunctionincluding Blindness And Muscle Weakness
